Graves' disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis

Conclusions. This is the first case of GD reported after ocrelizumab administration. The timing, onset and course of this case is similar to alemtuzumab-induced GD, usually interpreted as an "immune reconstitution syndrome"; however, ocrelizumab cell count depletion is inferior in severity, cell population affected and duration of depletion. This case highlights the importance of pre-screening and follow-up with thyroid function tests in patients treated with ocrelizumab. As a novel therapeutic antibody, further investigation is required to unravel the causes of thyroid autoimmunity.PMID:34523298 | DOI:10.2478/enr-2021-0018

Source: Endocrine Regulations - September 15, 2021 Category: Endocrinology Authors: Diana Borges Duarte Ana Martins da Silva Claudia Freitas Helena Cardoso Source Type: research